Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,444 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pharmacodynamics Clear all

Conditions: Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions: STSA-1002 subcutaneous injection; Drug
Lead sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd; Industry
Eligibility: 21 Years to 57 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pompe Disease
Interventions: BMN 701; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 13 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Kansas City, Kansas

Conditions: Healthy
Interventions: JNJ-26366821, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Cancer
Interventions: PF-05212384, PD-0325901, irinotecan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL747, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Salt Lake City, Utah

Conditions: Heart Failure, Diastolic Heart Failure
Interventions: KNO3, KCl; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metabolism
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Drug Interaction
Interventions: Efavirenz; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Hypoglycemia
Interventions: BHT-3021, BHT-Placebo; Drug
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more

Conditions: Thromboembolism
Interventions: Apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 18
States / cities: Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more

Conditions: Diabetes Mellitus
Interventions: AMG 876; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Chula Vista, California • Miramar, Florida • Overland Park, Kansas + 3 more

Conditions: Friedreich Ataxia
Interventions: Nomlabofusp, Placebo; Drug
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Open-angle Glaucoma
Interventions: PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham; Drug
Lead sponsor: Perfuse Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain, Ventilatory Depression
Interventions: hydromorphone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: Carcinoma, Renal Cell
Interventions: GW786034, lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions: AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, ECC5004; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: SAGE-217 high dose, Placebo, SAGE-217 low dose; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Anesthesia, Dental
Interventions: Phentolamine Mesylate (NV-101); Drug
Lead sponsor: Novalar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Hyperopia, Myopia
Interventions: 1% EXP039, Saline control; Drug · Other
Lead sponsor: Canyon City Eyecare; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Azusa, California

Search by objective public record fields.

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

Influence of Age and Sex on Alcohol Metabolism and Acute Responses

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

A Study of PER-001 in Participants With Open-Angle Glaucoma

Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

FTIH of ECC5004 in Healthy and Diabetic Participants

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia